PROCHLORPERAZINE MALEATE | A040268 | JUBILANT CADISTA PHARMACEUTICALS INC
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Citizen Petition from Lachman Consulting Services, Inc. FDA-2020-P-0598 · 5 docket documents Lachman Consulting Services, Inc. filed this petition requesting the FDA designate Prochlorperazine Maleate Tablets USP, 10 mg (A040268) of Jubilant Cadista Pharmaceuticals Inc. as a reference standard, or a suitable alternative reference standard, for in vivo bioequivalence studies to support an AN | 505(q) | 2020-02-04 | Withdrawn | Lachman Consulting Services, Inc. |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$0.1741
per ea
Lowest NADAC/Unit
$0.1155
per ea
Brand NDCs
0
Generic NDCs
4
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 50268068515PROCHLORPERAZINE 10 MG TAB | $0.1741 | EA | Generic | — | 2026-06-17 |
| 59746011506PROCHLORPERAZINE 10 MG TAB | $0.1741 | EA | Generic | — | 2026-06-17 |
| 50268068415PROCHLORPERAZINE 5 MG TABLET | $0.1155 | EA | Generic | — | 2026-06-17 |
| 59746011306PROCHLORPERAZINE 5 MG TABLET | $0.1155 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.